Intensive lipid intervention in the post-ENHANCE era

Mayo Clinic Proceedings

Volumn 83, Issue 8, 2008, Pages 867-869

  O'Keefe, James H ^a,c   Bybee, Kevin A ^a   Lavie, Carl J ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 49249089489     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.8.867     Document Type: Editorial

References (28)

1. Shepherd J, Kastelein JJP, Bittner VA, et al; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83(8):870-879.
2. Harper C, Jacobson T. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375-2384.
3. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? the safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy [published correction appears in J Am Coll Cardiol. 2006; 47(2):472]. J Am Coll Cardiol. 2005;46(8):1411-1416.
4. Schwartz GG, Olsson AG, Ezekowitz MD, et al, Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
5. Amarenco P, Bogousslavsky J, Callahan A III, et al, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
6. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17(2):92-100.
7. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007 Feb 6;115(5):576-583. Epub 2007 Jan 29.
8. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin. 2008 Apr;24(4):1217-1229. Epub 2008 Mar 20.
9. Shepherd J, Kastelein JJ, Bittner V, et al, Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-1139. Epub 2007 Oct 17.
10. Carey J. Do cholesterol drugs do any good? BusinessWeek. January 17, 2008.
11. Carey J. Heart disease: not about cholesterol? BusinessWeek. 2008.
12. Kastelein JJ, Akdim F, Stroes ES, et al, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia [published correction appears in N Engl J Med. 2008;358(18):1977]. N Engl J Med. 2008 Apr 3;358(14): 1431-1443. Epub 2008 Mar 30.
13. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke. 2003 Dec;34(12):2985-2994. Epub 2003 Nov 13.
14. Crouse JR III, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344-1353. Epub 2007 Mar 25.
15. Nissen SE, Tuzcu EM, Schoenhagen P, et al, REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.
16. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-1565. Epub 2006 Mar 13.
17. Pfizer. Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women: a Randomized Evaluation of atorvastatin, versus placebo (CASHMERE). http://www.clinicaltrials.gov/ct2/show/record/NCT00163163. Accessed July 11, 2008.
18. Lavie CJ, Milani RV, O'Keefe JH. Statin wars: emphasis on potency vs event reduction and safety [editorial]? Mayo Clin Proc. 2007;82(5):539-542.
19. Menuet R, Lavie CJ, Milani RV. Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci. 2005;330(6):295-302.
20. Lavie CJ, Milani RV. Lipid therapy in the elderly-emphasis on clinical event reduction and safety. Am J Geriatr Cardiol. 2006;15(4):245-247.
21. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol. 2007 Mar 13;49(10):1035-1042. Epub 2007 Feb 23.
22. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal lowdensity lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142-2146.
23. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update [published correction appears in Circulation. 2006;113(22):e847]. Circulation. 2006;113(19):2363-2372.
24. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366(9494):1358]. Lancet. 2005 Oct 8;366(9493):1267-1278. Epub 2005 Sep 27.
25. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007 May 1;49(17):1753-1762. Epub 2007 Apr 16.
26. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108(19):2292-2297.
27. AstraZeneca International Web site. Crestor outcomes study JUPITER closes early due to unequivocal evidence of benefit. http://astrazeneca.com/ pressrelease/5385.aspx. March 31, 2008. Accessed July 3, 2008.
28. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43(6):1056-1061.